Titan Medical Appoints Stephen Lemieux as CFO

Titan Medical Inc., a medical device company focused on the design and development of surgical technologies for robotic single access surgery, has appointed Stephen Lemieux as chief financial officer (CFO). Lemieux has more than 18 years of experience working in Nasdaq and TSX listed companies primarily focused in the health care industry.

Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at more than $400 million. Previously, Lemieux served as CFO and secretary of NeuPath Health Inc. Lemieux is a chartered professional accountant and earned a master’s of Management & Professional Accounting degree from the University of Toronto.
 
“Titan is an innovation leader in robotic single access surgery, and I believe this is an exciting time to be joining Titan as the Enos robotic single access surgical system advances toward several significant milestones. I am pleased to be joining such a talented and dedicated team,” said Lemieux. “I look forward to providing my financial expertise and capital markets experience to support Titan’s goals and upcoming milestones.”
 
“We are excited to welcome Stephen to Titan,” said David McNally, president and CEO. “His wealth of knowledge and experience will be instrumental in helping Titan evolve our financial systems and capital markets strategy, achieve upcoming milestones, and executing upon our vision.”
 
Former CFO Monique Delorme will remain with the company in an advisory capacity through March 2022 to ensure a smooth transition.
 
“We would like to thank Monique for her contributions to Titan through a period of great change. Despite the COVID-19 pandemic, during the past 12 months we executed development and license agreements with Medtronic, built out and staffed a research and development facility in Chapel Hill, North Carolina and completed several financings, all of which would not have been possible without Monique’s support,” said McNally. “We are grateful for her commitment and tireless effort and consummate professionalism through this transition period.”
 
“It has been a privilege to work alongside David and the team at Titan. I have great confidence in the company’s ability to achieve its strategic and financial goals and believe Titan is well-positioned to capitalize on opportunities for value creation,” Delorme said. “I am grateful for my time at the company and look forward to working with the leadership and finance teams to ensure a seamless transition.”
 
Titan Medical Inc. is a medical device company headquartered in Toronto, with R&D facilities in Chapel Hill, N.C. It is focused on enhancing robotic assisted surgery using technology through a single access point. The Enos robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand, and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.